Title 21, Food and DrugsRelease 119-110

§379dd–2 Activities of the Food and Drug Administration

Title 21 › CHAPTER 9 — FEDERAL FOOD, DRUG, AND COSMETIC ACT › SUBCHAPTER VII — GENERAL AUTHORITY › Part I — Reagan-Udall Foundation for the Food and Drug Administration › § 379dd–2

Last updated Sep 22, 2026|Official source

Summary

The Commissioner must get and review the report the Foundation’s Executive Director sends under the law. Starting with fiscal year 2009, the Commissioner must send Congress a yearly summary explaining how the FDA used information from that Foundation report and from other grant, contract, MOU, or cooperative‑agreement recipients in its regulatory and product‑review work. The rules in this part and in section 360bbb–5 do not change or affect any FDA grant, contract, MOU, or cooperative agreement made before, on, or after September 27, 2007.

Full Legal Text

Title 21, §379dd–2

Food and Drugs, Source: USLM XML via OLRC

(a)In general

The Commissioner shall receive and assess the report submitted to the Commissioner by the Executive Director of the Foundation under section 379dd(l)(2) of this title.

(b)Report to Congress

Beginning with fiscal year 2009, the Commissioner shall submit to Congress an annual report summarizing the incorporation of the information provided by the Foundation in the report described under section 379dd(l)(2) of this title and by other recipients of grants, contracts, memoranda of understanding, or cooperative agreements into regulatory and product review activities of the Food and Drug Administration.

(c)Extramural grants

The provisions of this part and section 360bbb–5 of this title shall have no effect on any grant, contract, memorandum of understanding, or cooperative agreement between the Food and Drug Administration and any other entity entered into before, on, or after September 27, 2007.

Reference

Citations & Metadata

Citation

21 U.S.C. § 379dd–2

Title 21, Food and Drugs

Last Updated

Sep 22, 2026

Release point: 119-110